> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# West Pharmaceutical's New CEO Says The Bar For Acquisitions Is 'Incredibly High' As Customers Cut Supplier Lists
- URL: https://www.bullished.co/west-pharmaceuticals-new-ceo-says-the-bar-for-acquisitions-is-incredibly-high-as-customers-6faf3bb0/
- Published: 2026-10-29T14:06:27.000Z
- Updated: 2026-10-30T02:19:35.000Z
- Description: CEO Michele Lagarde, two months into the job, says West will stay organic and patient while its customers consolidate suppliers.
- Author: Matteo Parrino
- Tags: Earnings, WST, Industry: Healthcare

[West Pharmaceutical](https://www.bullished.co/tag/wst/) CEO Michele Lagarde, two months into the job, told analysts on the company's [third-quarter earnings call](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) on Thursday that "the bar for M&A is incredibly high." West will pursue only deals that truly amplify its financial profile, she said, even as customers push to shrink their supplier bases.

## Patience on deals, by design

West, which makes containment and delivery systems for injectable drugs, such as stoppers, seals, syringe components and self-injection devices, drew the M&A question from an analyst at UBS. He asked about portfolio gaps and her criteria, and noted her decade at Thermo.

Lagarde did not take up that history. She said it is early, and that high bar is "a good thing" because it lets West be "incredibly patient, disciplined." On the organic path, she said, "the [organic focus](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co), I think, is what it will be," and she will weigh other opportunities as she goes through the process.

She tied the stance to what customers tell her. After calling on many of them for a decade, she said, they want "[simplification](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) of their supply chain and consolidation of their supplier base," and are vocal that they would move market share toward preferred partners. West, she said, is on a very short list, which invites the question of what else it could offer them.

## A quarter that gave her room

Revenue in the quarter was [$874 million](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co), up 12% organically, and adjusted earnings per share were $2.66, up 36% from a year earlier, Lagarde said. Chief Financial Officer Bob McMahon said high-value proprietary components grew 20% organically to $467 million, and GLP-1-related components in that line grew well into the 30s.

West raised full-year guidance. Revenue is now expected at [$3.41 billion](https://markets.ft.com/data/announce/detail?dockey=600-202610290600PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE84028-1&ref=bullished.co) to $3.42 billion, up from $3.345 billion to $3.38 billion, and adjusted EPS at $9.38 to $9.48, up from $8.85 to $9.05.

Lagarde said West is on track to deliver more than 40 billion critical components to customers this year. The stock carried a market value of $28.4 billion in Thursday morning trading.

## Capacity and what comes next

McMahon said West is starting a new round of investment to expand finishing capacity in Europe and the US, and expects capital spending to stay within 6% to 8% of revenue. Lagarde said the projects go into the existing footprint and would take roughly 18 to 24 months to come online.

She also said she spent her first two months visiting sites, including the Ashweiler plant in Germany, and meeting customers and investors.

West plans to introduce 2027 guidance on its fourth-quarter call in February.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [West Pharmaceutical Servs Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62694662/west-pharmaceutical-servs-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates](https://finance.yahoo.com/markets/stocks/articles/west-pharmaceutical-services-wst-q3-101003271.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [West Pharmaceutical beats top-line and bottom-line estimates; raises FY26 outlook | Seeking Alpha](https://seekingalpha.com/news/4659985-west-pharmaceutical-beats-top-line-and-bottom-line-estimates-raises-fy26-outlook?ref=bullished.co) — seekingalpha.com
- [West Pharmaceutical: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/west-pharmaceutical-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [West Reports Third-Quarter 2026 Results – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610290600PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE84028-1&ref=bullished.co) — Financial Times

### More on West Pharmaceutical

- [West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report](https://www.bullished.co/west-pharmaceutical-refinanced-203-0-million-of-2027-debt-just-before-its-quarterly-report-b5e60343/)
- [West Pharmaceutical Stock Surges 7%, Adding $1.9 Billion, As Company Lifts 2026 Outlook](https://www.bullished.co/west-pharmaceutical-stock-surges-7-adding-1-9-billion-as-company-lifts-2026-outlook-f0c470fb/)
- [West Pharmaceutical Says GLP-1 Surge Had 'Nothing One-Offish' — But Margins Are Not 'The New Floor'](https://www.bullished.co/west-pharmaceutical-says-glp-1-surge-had-nothing-one-offish-but-margins-are-not-the-new-6401a116/)

[All West Pharmaceutical (WST) coverage →](https://www.bullished.co/tag/wst/)